CLASS II Device recall · Reported 3 Jul 2019 · FDA Enforcement Report

RNeasy DSP FFPE Kit recalled by Qiagen Sciences

Qiagen Sciences is recalling RNeasy DSP FFPE Kit, distributed nationwide in the US. The recall was initiated on 6 May 2019 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLOT 163016105
Quantity recalled31

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1891-2019
FDA event ID
82985
Recalling firm
Qiagen Sciences, Germantown, MD
Classification
Class II
Status
Terminated
Recall initiated
6 May 2019
FDA classified
27 Jun 2019
Reported
3 Jul 2019
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Other Reasons

Timeline

6 May 2019Recall initiated by company
27 Jun 2019Classified by FDA+52 days
3 Jul 2019Published in enforcement report+6 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The deparaffinization solution contains a contaminant, which leads to reduced lysis efficiency of the affected lot, resulting in significantly reduced yields and less sensitive downstream applications.

Product as listed by the FDA

RNeasy DSP FFPE Kit (48), REF 73604 - Product Usage: The RNeasy DSP FFPE Kit is a system intended for the purification of total RNA from formalin-fixed, paraffin embedded (FFPE) tissues. The product is intended to be used by professional users, such as technicians and physicians that are trained in molecular biological techniques. It deploys an optimized silica spin-column-based protocol, and includes enzymatic removal of residual DNA. The RNeasy DSP FFPE Kit is intended for in vitro diagnostic use.

Where it was distributed

US nationwide distribution in the states of MA, RI, AZ, NY, NC, IN, TX. The products were distributed to the following foreign countries: Germany, Great Britain, Italy, France, Sweden, and Switzerland.

Nationwide ArizonaIndianaMassachusettsNorth CarolinaNew YorkRhode IslandTexas

Questions about this recall

Why was it recalled?

The deparaffinization solution contains a contaminant, which leads to reduced lysis efficiency of the affected lot, resulting in significantly reduced yields and less sensitive downstream applications.

Which lots are affected?

LOT 163016105

Where was it sold?

US nationwide distribution in the states of MA, RI, AZ, NY, NC, IN, TX. The products were distributed to the following foreign countries: Germany, Great Britain, Italy, France, Sweden, and Switzerland.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Qiagen Sciences

All 23

Other Test Kits & Diagnostics recalls

All 2,675
ReportedClassRecallCompanyReasonWhere
DeviceCLASS IINextseq 550Dx Instrument recalled by IlluminaIlluminaOtherNationwide
DeviceCLASS IINovaSeq 6000Dx Instrument recalled by IlluminaIlluminaOtherNationwide
DeviceCLASS IILiaison Plex Gram-Negative Blood Culture Assay recalled by LuminexLuminexPotency & AssayNationwide
DeviceCLASS IIMiSeq Dx Instrument recalled by IlluminaIlluminaOtherNationwide
DeviceCLASS IITechno-Path Multichem AE Unassayed Level recalledTechno-path ManufacturingPotency & AssayNationwide